|Licence data||US FDA:|
|Legal status||℞-only (US)|
|Mol. mass||146.1 kDa|
| (what is this?)
Ofatumumab (trade name Arzerra, also known as HuMax-CD20) is a human monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating Follicular non-Hodgkin’s lymphoma, Diffuse large B cell lymphoma, rheumatoid arthritis and relapsing remitting multiple sclerosis. Ofatumumab has also received conditional approval in Europe for the treatment of refractory chronic lymphocytic leukemia. This makes ofatumumab the first marketing application for an antibody produced by Genmab, as well as the first human monoclonal antibody which targets the CD20 molecule that will be available for patients with refractory CLL.
Ofatumumab targets an epitope different from rituximab and most other CD20 directed antibodies. Ofatumumab binds to both the small and large loops of the CD20 molecule on B cells. Its location is in closer proximity to the membrane, which in theory allows for more effective complement deposition and subsequent B cell killing. The CD20 molecule is highly expressed in both normal and malignant B cells.
Approvals and indications 
It was approved by FDA in Oct 2009 for chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab. It was conditionally approved by the EMA for refractory chronic lymphocytic leukemia in 2010.
Clinical trials 
Status of clinical trials of ofatumumab conducted by Genmab and GSK, as of late 2010.
- Relapsed follicular non-Hodgkin's lymphoma (NHL)-Phase III 
- Rheumatoid arthritis (RA):
- Diffuse large B cell lymphoma (DLBCL) – Phase III
- B-cell chronic lymphocytic leukemia (B-CLL) – Phase III
- Waldenstrom's Macroglobulinemia - Phase II 
- Relapsing Remitting Multiple Sclerosis (RRMS)-Phase II 
- Mantle cell lymphoma (MCL)
See also 
- Zhang, Bodi (2009). "Ofatumumab". MAbs 1 (4): 326–331. doi:10.4161/mabs.1.4.8895. PMC 2726602. PMID 20068404.
- FDA Approves Ofatumumab (Arzerra) for Patients With CLL Refractory to Fludarabine and Alemtuzumab, October 2009
- ClinicalTrials.gov NCT00611455 Investigating Clinical Efficacy of Ofatumumab in Adult RA Patients Who Had an Inadequate Response to MTX Therapy
- ClinicalTrials.gov NCT00603525 Investigating Clinical Efficacy of Ofatumumab in Adult RA Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
- ClinicalTrials.gov NCTNCT01014208 Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma (ORCHARRD
- ClinicalTrials.gov NCT00349349 HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
- Coiffier B, Lepretre S, Pedersen LM, et al. (February 2008). "Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study". Blood 111 (3): 1094–100. doi:10.1182/blood-2007-09-111781. PMID 18003886.
- Zhang B (July 2009). "Ofatumumab". MAbs 1 (4): 326–31. doi:10.4161/mabs.1.4.8895. PMC 2726602. PMID 20068404.
- ClinicalTrials.gov: HuMax-CD20 search results
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|